Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced results from new post hoc analyses of the HELIOS-B Phase 3 study of AMVUTTRA® (vutrisiran), an RNAi ...

Chronic kidney disease is a gradual, irreversible loss of kidney function caused by diabetes, hypertension, or ageing. It ...

Blocking fatty ceramides could stop acute kidney injury—and possibly revolutionize mitochondrial disease treatment.

A mismatch between two common tests for kidney function may indicate a higher risk for kidney failure, heart disease, and ...

The results of two large-scale studies demonstrate that sodium-glucose co-transporter 2 (SGLT2) inhibitors significantly ...

If the drug works in people, it could prevent kidney injury in high-risk populations, or potentially even treat other ...

A research team at the University of Pittsburgh, led by Dr. Anne Robertson and PhD candidate Fatemeh Azari, discovered that the bladder does not simply inflate like a balloon when it fills. Instead, ...

3D printing technology enables precise drug design, personalized dosing, and versatile release modes, benefiting patient-centric treatments. At AAPS PharmSci 360, Xialing Li, PhD, says 3D-printed ...

HOUSTON -- Two commonly used kidney function tests had a large degree of disagreement and were linked with serious health ...

Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced new data from the Phase 3 DUPLEX Study demonstrating that patients with focal segmental glomerulosclerosis (FSGS) treated with FILSPARI® ...

It also took the spot as the 12th leading cause of disability-adjusted life-years (DALYs), with an age-standardized DALY rate ...